Please assess the completion status of the following clinical trial:

Trial Title: AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed unresectable locally advanced or metastatic gastric or esophagogastric junction (EGJ) adenocarcinoma; tumors of the distal esophagus within 5 cm of the EGJ are eligible~* ECOG performance status 0 or 1~* Male or female ≥ 18 years of age~Exclusion Criteria:~* Previous systemic therapy (chemotherapy or biologic therapy) for locally advanced or metastatic gastric or esophagogastric adenocarcinoma~* Less than 6 months have elapsed from completion of prior neoadjuvant or adjuvant chemotherapy or chemoradiotherapy.~* Subjects with resectable disease or suitable for definitive chemoradiation~* Subjects with persistent gastric outlet obstruction, complete dysphagia or feeding jejunostomy~* Tumors of squamous cell histology~* Known central nervous system metastases~* Clinically significant upper gastro-intestinal bleeding ≤ 30 days prior to enrollment or randomization~* Serious or non-healing wound

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 2 Arm C (Type: PLACEBO_COMPARATOR): AMG 102 placebo plus ECX
- Phase 1b (Type: OTHER): Phase 1b dose study with open-labe AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed.
- Phase 2 Arm B (Type: ACTIVE_COMPARATOR): AMG 102 at 7.5mg/kg plus ECX
- Phase 2 Arm A (Type: ACTIVE_COMPARATOR): AMG 102 at 15mg/kg plus ECX

Based on this trial design, predict the completion outcome and termination type (if applicable).